Molecular profiling of pancreatic neuroendocrine tumors (pNETS) and the clinical potential

References

• Oberg K, Jelic S, ESMO Guidelines Working Group. Neuroendocrine gastroenteropancreatic tumors: ESMO clinical recommendation for diagnosis, treatment and follow-up. Ann Oncol. 2009;20(suppl4):iv150–iv153.
   Google Scholar
• McKenna LR, Edil BH. Update on pancreatic neuroendocrine tumors. Gland Surgery. 2014;3:258–275.
   PubMedGoogle Scholar
• Fraenkel M, Kim MK, Faggiano A, et al. Epidemiology of gastroenteropancreatic neuroendocrine tumours. Best Pract Res Clin Gastroenterol. 2012;26(6):691–703.
   PubMed Web of Science ®Google Scholar
• Lawrence B, Gustafsson BI, Chan A, et al. The epidemiology of gastroenteropancreatic neuroendocrine tumors. Endocrinol Metab Clin North Am. 2011;40:1–18.
   PubMed Web of Science ®Google Scholar
• Yao JC, Hassan M, Phan A, et al. One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26:3063–3072.
   PubMed Web of Science ®Google Scholar
• Modlin IM, Oberg K, Chung DC, et al. Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol. 2008;9:61–72.
   PubMed Web of Science ®Google Scholar
• Jensen RT, Cadiot G, Brandi ML, et al. ENETS consensus guidelines for the management of patients with digestive neuroendocrine neoplasms: functional pancreatic endocrine tumor syndromes. Neuroendocrinology. 2011;95:98–119.
   Web of Science ®Google Scholar
• Bosman FT, Carneiro F, Hruban RH, et al. WHO classification of tumours of the digestive system. 4th ed. World Health Organization. 2010.
   Google Scholar
• Vortmeyer AO, Huang S, Lubensky I, et al. Non-islet origin of pancreatic islet cell tumors. J Clin Endocrinol Metab. 2004;89:1934–1938.
   PubMed Web of Science ®Google Scholar
• Grozinsky‐Glasberg S, Mazeh H, Gross DJ. Clinical features of pancreatic neuroendocrine tumors. J Hepatobiliary Pancreatic Sci. 2015;22:578–585.
   PubMed Web of Science ®Google Scholar
• Durante C, Boukheris H, Dromain C, et al. Prognostic factors influencing survival from metastatic (stage IV) gastroenteropancreatic well-differentiated endocrine carcinoma. Endocr Relat Cancer. 2009;16:585–597.
   PubMed Web of Science ®Google Scholar
• Halfdanarson TR, Rabe KG, Rubin J, et al. Pancreatic neuroendocrine tumors (PNETs): incidence, prognosis and recent trend toward improved survival. Ann Oncol. 2008;19:1727-1733.
   PubMed Web of Science ®Google Scholar
• Jiao Y, Shi C, Edil BH, et al. DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science. 2011;331:1199–1203.
   PubMed Web of Science ®Google Scholar
• Lemos MC, Thakker RV. Multiple endocrine neoplasia type 1 (MEN1): analysis of 1336 mutations reported in the first decade following identification of the gene. Hum Mutat. 2008;29:22–32.
   PubMed Web of Science ®Google Scholar
• Jensen RT, Berna MJ, Bingham DB, et al. Inherited pancreatic endocrine tumor syndromes: advances in molecular pathogenesis, diagnosis, management, and controversies. Cancer. 2008;113:1807–1843.
   PubMed Web of Science ®Google Scholar
• Moore PS, Missiaglia E, Antonello D, et al. Role of disease‐causing genes in sporadic pancreatic endocrine tumors: MEN1 andVHL. Genes Chromosomes Cancer. 2001;32:177–181.
   PubMed Web of Science ®Google Scholar
• Corcos O, Couvelard A, Giraud S, et al. Endocrine pancreatic tumors in von Hippel-Lindau disease: clinical, histological, and genetic features. Pancreas. 2008;37:85–93.
   PubMed Web of Science ®Google Scholar
• Schmitt AM, Schmid S, Rudolph T, et al. VHL inactivation is an important pathway for the development of malignant sporadic pancreatic endocrine tumors. Endocr Relat Cancer. 2009;16:1219–1227.
   PubMed Web of Science ®Google Scholar
• Rosner M, Hanneder M, Siegel N, et al. The mTOR pathway and its role in human genetic diseases. Mutat Res Rev Mutat Res. 2008;659:284–292.
   PubMed Web of Science ®Google Scholar
• McClatchey AI. Neurofibromatosis. Annu Rev Pathol Mech Dis. 2007;2:191–216.
   PubMed Web of Science ®Google Scholar
• Brandi ML, Gagel RF, Angeli A, et al. Consensus: guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metabol. 2001;86(12):5658–5671.
   PubMed Web of Science ®Google Scholar
• Curatolo P, Bombardieri R. Tuberous sclerosis. Handb Clin Neurol. 2007;87:129–151.
   Google Scholar
• Inoue M, Hager JH, Ferrara N, et al. VEGF-A has a critical, nonredundant role in angiogenic switching and pancreatic β cell carcinogenesis. Cancer Cell. 2002;1:193–202.
   PubMed Web of Science ®Google Scholar
• Lammert E, Gu G, McLaughlin M, et al. Role of VEGF-A in vascularization of pancreatic islets. Curr Biol. 2003;13:1070–1074.
   PubMed Web of Science ®Google Scholar
• Lammert E, Cleaver O, Melton D. Induction of pancreatic differentiation by signals from blood vessels. Science. 2001;294:564–567.
   PubMed Web of Science ®Google Scholar
• Marion-Audibert AM, Barel C, Gouysse G, et al. Low microvessel density is an unfavorable histoprognostic factor in pancreatic endocrine tumors. Gastroenterol. 2003;125:1094–1104.
   PubMed Web of Science ®Google Scholar
• Couvelard A, O’Toole D, Turley H, et al. Microvascular density and hypoxia-inducible factor pathway in pancreatic endocrine tumours: negative correlation of microvascular density and VEGF expression with tumour progression. Br J Cancer. 2005;92:94–101.
   PubMed Web of Science ®Google Scholar
• Detjen KM, Rieke S, Deters A, et al. Angiopoietin-2 promotes disease progression of neuroendocrine tumors. Clin Cancer Res. 2010;16:420–429.
   PubMed Web of Science ®Google Scholar
• Ripka S, Neesse A, Riedel J, et al. CUX1: target of Akt signalling and mediator of resistance to apoptosis in pancreatic cancer. Gut. 2010;59:1101–1110.
   PubMed Web of Science ®Google Scholar
• Michl P, Ramjaun AR, Pardo OE, et al. CUTL1 is a target of TGFβ signaling that enhances cancer cell motility and invasiveness. Cancer Cell. 2005;7:521–532.
   PubMed Web of Science ®Google Scholar
• Krug S, Kühnemuth B, Griesmann H, et al. CUX1: a modulator of tumour aggressiveness in pancreatic neuroendocrine neoplasms. Endocr Rel Cancer. 2014;21:879–890.
   PubMed Web of Science ®Google Scholar
• Tang J, Wu S, Liu H, et al. A novel transcription regulatory complex containing death domain-associated protein and the ATR-X syndrome protein. J Biol Chem. 2004;279:20369–20377.
   PubMed Web of Science ®Google Scholar
• de Wilde RF, Edil BH, Hruban RH, et al. Well-differentiated pancreatic neuroendocrine tumors: from genetics to therapy. Nat Rev Gastroenterol Hepatol. 2012;9:199–208.
   PubMed Web of Science ®Google Scholar
• Ichihara M, Murakumo Y, Takahashi M. RET and neuroendocrine tumors. Cancer Lett. 2004;204:197–211.
   PubMed Web of Science ®Google Scholar
• Toker A. mTOR and Akt signaling in cancer: SGK cycles in. Mol Cell. 2008;31:6–8.
   PubMed Web of Science ®Google Scholar
• Zhang H, Cicchetti G, Onda H, et al. Loss of Tsc1/Tsc2 activates mTOR and disrupts PI3K-Akt signaling through downregulation of PDGFR. J Clin Invest. 2003;112:1223–1233.
   PubMed Web of Science ®Google Scholar
• Wang Y, Ozawa A, Zaman S, et al. The tumor suppressor protein menin inhibits AKT activation by regulating its cellular localization. Cancer Res. 2011;71:371–382.
   PubMed Web of Science ®Google Scholar
• Scarpa A, Chang DK, Nones K, et al. Whole-genome landscape of pancreatic neuroendocrine tumours. Nature. 2017;543:65–71.
   PubMed Web of Science ®Google Scholar
• Rossi RE, Massironi S, Conte D, et al. Therapy for metastatic pancreatic neuroendocrine tumors. Ann Transl Med. 2013;2:8.
   Google Scholar
• Smith JK, Ng SC, Hill JS, et al. Complications after pancreatectomy for neuroendocrine tumors: a national study. J Surg Res. 2010;163:63–68.
   PubMed Web of Science ®Google Scholar
• Caplin ME, Pavel M, Ćwikła JB, et al. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med. 2014;371:224–233.
   PubMed Web of Science ®Google Scholar
• Van Vliet EI, Teunissen JJ, Kam BL, et al. Treatment of gastroenteropancreatic neuroendocrine tumors with peptide receptor radionuclide therapy. Neuroendocrinol. 2012;97:74–85.
   PubMed Web of Science ®Google Scholar
• Yao JC, Tsuchihashi Z, Panneerselvam A, et al. Everolimus for the treatment of advanced pancreatic neuroendocrine tumors: overall survival and circulating biomarkers from the randomized, phase III RADIANT-3 study. J Clin Oncol. 2016;34:3906–3913.
   PubMed Web of Science ®Google Scholar
• Fjällskog MLH, Lejonklou MH, Öberg KE, et al. Expression of molecular targets for tyrosine kinase receptor antagonists in malignant endocrine pancreatic tumors. Clin Cancer Res. 2003;9:1469–1473.
   PubMed Web of Science ®Google Scholar
• Raymond E, Dahan L, Raoul JL, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. New Engl J Med. 2011;364:501–513.
   PubMed Web of Science ®Google Scholar
• Kulke MH, Niedzwiecki D, Foster NR, et al. Randomized phase II study of everolimus (E) versus everolimus plus bevacizumab (E+ B) in patients (Pts) with locally advanced or metastatic pancreatic neuroendocrine tumors (pNET), CALGB 80701 (Alliance). ASCO Annu Meet Proc. 2015;33(suppl):4005.
   Google Scholar
• Mologni L. Development of RET kinase inhibitors for targeted cancer therapy. Curr Med Chem. 2011;18:162–175.
   PubMed Web of Science ®Google Scholar
• Zhang J, Francois R, Iyer R, et al. Current understanding of the molecular biology of pancreatic neuroendocrine tumors. J Natl Cancer Instit. 2013;105:1005–1017.
   PubMedGoogle Scholar
• Strosberg J, El-Haddad G, Wolin E, et al. 177Lu-Dotatate for midgut neuroendocrine tumors. N Engl J Med. 2017;376:1390–1392.
   Google Scholar
• Dupuy A, Simon RM. Critical review of published microarray studies for cancer outcome and guidelines on statistical analysis and reporting. J Natl Cancer Insti. 2007;99:147–157.
   PubMed Web of Science ®Google Scholar
• Roldo C, Missiaglia E, Hagan JP, et al. MicroRNA expression abnormalities in pancreatic endocrine and acinar tumors are associated with distinctive pathologic features and clinical behavior. J Clin Oncol. 2006;24:4677–4684.
   PubMed Web of Science ®Google Scholar